Tirzepatide proved that dual GLP-1/GIP agonism outperforms GLP-1 alone. Retatrutide adds glucagon. Here is what that third agonist mechanism actually contributes to metabolic research.
Tirzepatide (Mounjaro/Zepbound) established that dual GLP-1/GIP agonism produces meaningfully better metabolic outcomes than GLP-1 single agonism. With approximately 20-21% body weight reduction in pivotal SURMOUNT trials — compared to roughly 15% for semaglutide — tirzepatide proved the value of adding GIP to the GLP-1 mechanism. Retatrutide is the next step: a triple agonist that adds glucagon receptor activation to the GLP-1/GIP platform.
This comparison examines what the glucagon receptor agonism adds, based on available phase 2 data and mechanistic research. For a broader overview of Retatrutide's full research profile, see the Complete Retatrutide Research Guide.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates: - GLP-1R: Reduces appetite, slows gastric emptying, stimulates glucose-dependent insulin secretion - GIPR: Amplifies insulin secretion, modulates adipose tissue biology, synergizes with GLP-1 through incompletely defined central mechanisms
Retatrutide adds glucagon receptor (GCGR) agonism to this dual platform. Glucagon is the counter-regulatory hormone to insulin — its receptor activation produces effects that are qualitatively different from GLP-1 and GIP: - Hepatic lipid oxidation: Glucagon directly stimulates beta-oxidation of fatty acids in the liver, reducing hepatic fat - Thermogenesis: GCGR activation upregulates UCP-1 (uncoupling protein-1) in brown adipose tissue, increasing energy expenditure and heat generation - Lipolysis: Glucagon mobilizes stored triglycerides from adipose tissue, increasing circulating free fatty acids for oxidation
In simple terms, GLP-1 and GIP primarily work by reducing energy intake. Glucagon additionally increases energy expenditure — operating on the output side of the energy balance equation simultaneously.
Tirzepatide SURMOUNT-1 phase 3 data (15mg, highest dose): approximately 21% body weight reduction over 72 weeks.
Retatrutide phase 2 data (NEJM 2023, 48 weeks): - 8mg cohort: approximately 17.5% body weight reduction - 12mg cohort: approximately 24.2% body weight reduction
The comparison requires careful reading: Retatrutide's phase 2 ran for 48 weeks, while tirzepatide's pivotal data reflects 72 weeks. At a shorter duration, Retatrutide's 12mg cohort surpassed tirzepatide's 72-week result. Phase 3 data at 72 weeks could plausibly extend further.
One of the most interesting mechanistic distinctions between tirzepatide and Retatrutide for research purposes is the glucagon component's effect on hepatic fat. GCGR activation directly stimulates hepatic beta-oxidation — breaking down liver fat independent of caloric restriction. This makes Retatrutide potentially more relevant for research into non-alcoholic fatty liver disease (NAFLD/NASH) than dual agonists alone. The liver has high glucagon receptor expression, making hepatic fat biology one of the primary differentiation areas for the triple agonist.
Both compounds produce primarily GI side effects (nausea, diarrhea, vomiting) concentrated during dose escalation. Retatrutide's glucagon agonism adds theoretical concern about hyperglycemia risk at high doses, since glucagon is gluconeogenic — though the GLP-1/GIP components appear to largely counterbalance this in the phase 2 data. No unexpected safety signals were reported in Retatrutide's phase 2 publication.
Tirzepatide has substantially more real-world data given its commercial approval. Retatrutide is in phase 3 development.
For researchers, the key question is whether glucagon agonism is part of the biology under investigation: - GLP-1/GIP biology only: Tirzepatide is the cleaner research tool with more available data - Combined incretin + glucagon receptor signaling: Retatrutide is the only available triple agonist for this mechanistic territory - Hepatic fat and thermogenesis research: Retatrutide's glucagon component makes it specifically relevant - Maximal weight reduction modeling: Retatrutide's phase 2 data produces the highest documented peptide-mediated weight reduction in current research
Both compounds are available from Corevanta for laboratory research applications.
[Retatrutide](/products/retatrutide) is available in 5mg, 10mg, 20mg, and 30mg lyophilized vials at ≥99% HPLC purity. For research use only.
Research compounds discussed in this article
All compounds discussed in this article are sold by Corevanta for laboratory research purposes only. They are not approved drugs, not dietary supplements, and are not intended for human consumption or therapeutic use. Always comply with applicable local regulations.